{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,9,2]],"date-time":"2024-09-02T05:52:13Z","timestamp":1725256333502},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2014,10,10]],"date-time":"2014-10-10T00:00:00Z","timestamp":1412899200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Med"],"published-print":{"date-parts":[[2015,11]]},"DOI":"10.1007\/s10238-014-0317-2","type":"journal-article","created":{"date-parts":[[2014,10,9]],"date-time":"2014-10-09T11:06:59Z","timestamp":1412852819000},"page":"493-499","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["De novo deletion 17p13.1 as a predictor for disease progression in chronic lymphocytic leukemia"],"prefix":"10.1007","volume":"15","author":[{"given":"Amro M. S.","family":"El-Ghammaz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Essam","family":"Abdelwahed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nevine N.","family":"Mostafa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dina A.","family":"Mansour","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,10,10]]},"reference":[{"key":"317_CR1","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1182\/asheducation-2013.1.138","volume":"2013","author":"M Hallek","year":"2013","unstructured":"Hallek M. Signaling the end of chronic lymphocytic leukemia: new frontline treatment strategies. Hematol Am Soc Hematol Educ Progr. 2013;2013:138\u201350.","journal-title":"Hematol Am Soc Hematol Educ Progr"},{"issue":"Supplement 4","key":"317_CR2","doi-asserted-by":"crossref","first-page":"iv51","DOI":"10.1093\/annonc\/mdn196","volume":"19","author":"M Hallek","year":"2008","unstructured":"Hallek M. Prognostic factors in chronic lymphocytic leukemia. Ann Oncol. 2008;19(Supplement 4):iv51\u20133.","journal-title":"Ann Oncol"},{"issue":"16","key":"317_CR3","doi-asserted-by":"crossref","first-page":"2223","DOI":"10.1200\/JCO.2010.32.0838","volume":"29","author":"D Gonzalez","year":"2011","unstructured":"Gonzalez D, Martinez P, Wade R, et al. Mutational status of the TP53 gene as a predictor of response and survival in patients with chronic lymphocytic leukemia: results from the LRF CLL4 Trial. J Clin Oncol. 2011;29(16):2223\u20139.","journal-title":"J Clin Oncol"},{"issue":"1","key":"317_CR4","doi-asserted-by":"crossref","first-page":"12","DOI":"10.3324\/haematol.2009.016873","volume":"95","author":"C Moreno","year":"2010","unstructured":"Moreno C, Montserrat E. Genetic lesions in chronic lymphocytic leukemia: What\u2019s ready for prime time use? Haematologica. 2010;95(1):12\u20135.","journal-title":"Haematologica"},{"key":"317_CR5","doi-asserted-by":"crossref","first-page":"3994","DOI":"10.1200\/JCO.2008.21.1128","volume":"27","author":"S Stilgenbauer","year":"2009","unstructured":"Stilgenbauer S, Zenz T, Winkler D, et al. Subcutaneous alemtuzumab in fludarabine-refractory chronic lymphocytic leukemia: clinical results and prognostic marker analyses from the CLL2H study of the German Chronic Lymphocytic Leukemia Study Group. J Clin Oncol. 2009;27:3994\u20134001.","journal-title":"J Clin Oncol"},{"issue":"2","key":"317_CR6","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.leukres.2010.08.023","volume":"35","author":"N Zainuddin","year":"2011","unstructured":"Zainuddin N, Murray F, Kanduri M, et al. TP53 mutations are infrequent in newly-diagnosed chronic lymphocytic leukemia. Leuk Res. 2011;35(2):272\u20134.","journal-title":"Leuk Res"},{"issue":"5","key":"317_CR7","doi-asserted-by":"crossref","first-page":"675","DOI":"10.3324\/haematol.2012.069369","volume":"98","author":"R Fo\u00e0","year":"2013","unstructured":"Fo\u00e0 R, Del Giudice I, Guarini A, et al. Clinical implications of the molecular genetics of chronic lymphocytic leukemia. Haematologica. 2013;98(5):675\u201385.","journal-title":"Haematologica"},{"key":"317_CR8","doi-asserted-by":"crossref","first-page":"4191","DOI":"10.1158\/1078-0432.CCR-11-2936","volume":"18","author":"K Lin","year":"2012","unstructured":"Lin K, Adamson J, Johnson GG, et al. Functional analysis of the ATM-p53-p21 pathway in the LRF CLL4 trial: blockade at the level of p21 is associated with short response duration. Clin Cancer Res. 2012;18:4191\u2013200.","journal-title":"Clin Cancer Res"},{"issue":"12","key":"317_CR9","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1038\/nrc2763","volume":"9","author":"CJ Brown","year":"2009","unstructured":"Brown CJ, Lain S, Verma CS, et al. Awakening guardian angels: drugging the p53 pathway. Nat Rev Cancer. 2009;9(12):862\u201373.","journal-title":"Nat Rev Cancer"},{"key":"317_CR10","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1182\/asheducation-2011.1.104","volume":"2011","author":"P Hillmen","year":"2011","unstructured":"Hillmen P. Using the biology of chronic lymphocytic leukemia to choose treatment. Hematol Am Soc Hematol Educ Progr. 2011;2011:104\u20139.","journal-title":"Hematol Am Soc Hematol Educ Progr"},{"key":"317_CR11","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1182\/blood-2009-03-210591","volume":"114","author":"CS Tam","year":"2009","unstructured":"Tam CS, Shanafelt TD, Wierda WG, et al. De novo deletion 17p13.1 chronic lymphocytic leukemia shows significant clinical heterogeneity: the M. D. Anderson and Mayo Clinic experience. Blood. 2009;114:957\u201364.","journal-title":"Blood"},{"key":"317_CR12","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1038\/leu.2008.260","volume":"23","author":"OG Best","year":"2009","unstructured":"Best OG, Gardiner AC, Davis ZA, et al. A subset of Binet stage A CLL patients with TP53 abnormalities and mutated IGHV genes have stable disease. Leukemia. 2009;23:212\u20134.","journal-title":"Leukemia"},{"key":"317_CR13","first-page":"4","volume":"1","author":"J Pei","year":"2012","unstructured":"Pei J, Jhanwar SC, Testa JR. Chromothripsis in a case of TP53-deficient chronic lymphocytic leukemia. Leuk Res Rep. 2012;1:4\u20136.","journal-title":"Leuk Res Rep"},{"key":"317_CR14","doi-asserted-by":"crossref","first-page":"5446","DOI":"10.1182\/blood-2007-06-093906","volume":"111","author":"M Hallek","year":"2008","unstructured":"Hallek M, Cheson BD, Catovsky D, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood. 2008;111:5446\u201356.","journal-title":"Blood"},{"key":"317_CR15","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1046\/j.0007-1048.2001.3205.x","volume":"116","author":"P Chevallier","year":"2002","unstructured":"Chevallier P, Penther D, Avet-Loiseau H, et al. CD38 expression and secondary 17p deletion are important prognostic factors in chronic lymphocytic leukaemia. Br J Haematol. 2002;116:142\u201350.","journal-title":"Br J Haematol"},{"key":"317_CR16","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1111\/j.1365-2141.2011.09000.x","volume":"157","author":"J Delgado","year":"2012","unstructured":"Delgado J, Espinet B, Oliveira AC, et al. Chronic lymphocytic leukaemia with 17p deletion: a retrospective analysis of prognostic factors and therapy results. Br J Haematol. 2012;157:67\u201374.","journal-title":"Br J Haematol"},{"key":"317_CR17","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1182\/blood.V85.6.1580.bloodjournal8561580","volume":"85","author":"H Dohner","year":"1995","unstructured":"Dohner H, Fischer K, Bentz M, et al. p53 gene deletion predicts for poor survival and non-response to therapy with purine analogs in chronic B-cell leukemias. Blood. 1995;85:1580\u20139.","journal-title":"Blood"},{"key":"317_CR18","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1056\/NEJM200012283432602","volume":"343","author":"H Dohner","year":"2000","unstructured":"Dohner H, Stilgenbauer S, Benner A, et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med. 2000;343:1910\u20136.","journal-title":"N Engl J Med"},{"key":"317_CR19","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1182\/blood.V100.4.1410.h81602001410_1410_1416","volume":"100","author":"A Krober","year":"2002","unstructured":"Krober A, Seiler T, Benner A, et al. V(H) mutation status, CD38 expression level, genomic aberrations, and survival in chronic lymphocytic leukemia. Blood. 2002;100:1410\u20136.","journal-title":"Blood"},{"key":"317_CR20","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1182\/blood.V100.4.1177.h81602001177_1177_1184","volume":"100","author":"DG Oscier","year":"2002","unstructured":"Oscier DG, Gardiner AC, Mould SJ, et al. Multivariate analysis of prognostic factors in CLL: clinical stage, IGVH gene mutational status, and loss or mutation of the p53 gene are independent prognostic factors. Blood. 2002;100:1177\u201384.","journal-title":"Blood"},{"key":"317_CR21","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1046\/j.1365-2141.2003.04265.x","volume":"121","author":"G Dewald","year":"2003","unstructured":"Dewald G, Brockman S, Paternoster S, et al. Chromosome anomalies detected by interphase fluorescence in situ hybridization: correlation with significant biological features of chronic lymphocytic leukemia. Br J Haematol. 2003;121:287\u201395.","journal-title":"Br J Haematol"},{"issue":"36","key":"317_CR22","first-page":"2537","volume":"88","author":"W Xu","year":"2008","unstructured":"Xu W, Li JY, Li L, et al. Fluorescent in situ hybridization with a panel of probes detects molecular cytogenetic abnormalities in patients with chronic lymphocytic leukemia. Zhonghua Yi Xue Za Zhi. 2008;88(36):2537\u201340.","journal-title":"Zhonghua Yi Xue Za Zhi"},{"issue":"11","key":"317_CR23","first-page":"334","volume":"139","author":"K Michalov\u00e1","year":"2000","unstructured":"Michalov\u00e1 K, Zemanov\u00e1 Z, Cmunt E, et al. The interphase fluorescence in situ hybridization (I-FISH) technique in patients with chronic lymphatic leukemia (CLL). Cas Lek Cesk. 2000;139(11):334\u20138.","journal-title":"Cas Lek Cesk"},{"issue":"7","key":"317_CR24","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1200\/JCO.2006.08.3089","volume":"25","author":"MR Grever","year":"2007","unstructured":"Grever MR, Lucas DM, Dewald GW, et al. Comprehensive assessment of genetic and molecular features predicting outcome in patients with chronic lymphocytic leukemia: results from the US intergroup Phase III trial E2997. J Clin Oncol. 2007;25(7):799\u2013804.","journal-title":"J Clin Oncol"},{"key":"317_CR25","doi-asserted-by":"crossref","first-page":"2589","DOI":"10.1182\/blood-2009-05-224071","volume":"114","author":"T Zenz","year":"2009","unstructured":"Zenz T, Habe S, Denzel T, et al. Detailed analysis of p53 pathway defects in fludarabine-refractory chronic lymphocytic leukemia (CLL): dissecting the contribution of 17p deletion, TP53 mutation, p53-p21 dysfunction, and miR34a in a prospective clinical trial. Blood. 2009;114:2589\u201397.","journal-title":"Blood"},{"key":"317_CR26","doi-asserted-by":"crossref","first-page":"4473","DOI":"10.1200\/JCO.2009.27.8762","volume":"28","author":"T Zenz","year":"2010","unstructured":"Zenz T, Eichhorst B, Busch R, et al. TP53 mutation and survival in chronic lymphocytic leukemia. J Clin Oncol. 2010;28:4473\u20139.","journal-title":"J Clin Oncol"},{"issue":"3","key":"317_CR27","doi-asserted-by":"crossref","first-page":"428","DOI":"10.3324\/haematol.2011.053512","volume":"97","author":"CLL Trialists\u2019 Collaborative Group","year":"2012","unstructured":"CLL Trialists\u2019 Collaborative Group. (CLLTCG). Systematic review of purine analog treatment for chronic lymphocytic leukemia: lessons for future trials. Haematologica. 2012;97(3):428\u201336.","journal-title":"Haematologica"},{"issue":"4","key":"317_CR28","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1182\/blood-2008-02-140582","volume":"112","author":"CS Tam","year":"2008","unstructured":"Tam CS, O\u2019Brien S, Wierda W, et al. Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia. Blood. 2008;112(4):975\u201380.","journal-title":"Blood"},{"issue":"8","key":"317_CR29","doi-asserted-by":"crossref","first-page":"2062","DOI":"10.1182\/blood-2011-01-329177","volume":"118","author":"SA Parikh","year":"2011","unstructured":"Parikh SA, Keating MJ, O\u2019Brien S, et al. Frontline chemoimmuno-therapy with fludarabine, cyclophosphamide, alemtuzumab, and rituximab for high-risk chronic lymphocytic leukemia. Blood. 2011;118(8):2062\u20138.","journal-title":"Blood"},{"key":"317_CR30","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1038\/leu.2009.133","volume":"23","author":"JE Castro","year":"2009","unstructured":"Castro JE, James DF, Sandoval-Sus JD, et al. Rituximab in combination with high-dose methylprednisolone for the treatment of chronic lymphocytic leukemia. Leukemia. 2009;23:1779\u201389.","journal-title":"Leukemia"},{"issue":"1","key":"317_CR31","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1056\/NEJMoa1215637","volume":"369","author":"JC Byrd","year":"2013","unstructured":"Byrd JC, Furman RR, Coutre SE, et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med. 2013;369(1):32\u201342.","journal-title":"N Engl J Med"},{"issue":"13","key":"317_CR32","doi-asserted-by":"crossref","first-page":"5094","DOI":"10.1200\/JCO.2008.16.2982","volume":"26","author":"J Schetelig","year":"2008","unstructured":"Schetelig J, van Biezen A, Brand R, et al. Allogeneic hematopoietic stem-cell transplantation for chronic lymphocytic leukemia With 17p deletion: a retrospective European Group for Blood and Marrow Transplantation analysis. J Clin Oncol. 2008;26(13):5094\u2013100.","journal-title":"J Clin Oncol"},{"issue":"8","key":"317_CR33","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1182\/blood-2012-09-458265","volume":"121","author":"D Rossi","year":"2013","unstructured":"Rossi D, Rasi S, Spina V, et al. Integrated mutational and cytogenetic analysis identifies new prognostic subgroups in chronic lymphocytic leukemia. Blood. 2013;121(8):1403\u201312.","journal-title":"Blood"}],"container-title":["Clinical and Experimental Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-014-0317-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10238-014-0317-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-014-0317-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,25]],"date-time":"2020-08-25T16:59:11Z","timestamp":1598374751000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10238-014-0317-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,10,10]]},"references-count":33,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2015,11]]}},"alternative-id":["317"],"URL":"https:\/\/doi.org\/10.1007\/s10238-014-0317-2","relation":{},"ISSN":["1591-9528"],"issn-type":[{"value":"1591-9528","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,10,10]]}}}